Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial (“REVEAL 1”) of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical dysplasia caused by human papillomavirus (HPV). Left untreated, cervical dysplasia can progress to cervical cancer. If approved, VGX-3100 would be the first immunotherapy and non-surgical alternative for women with late-stage cervical dysplasia.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares gained 19.84% to finally closed at $3.02 in last active session.
INO’s distance from 20 day simple moving average is 19.25% and distance from 50-Day simple moving average is -5.87%.
Analyst’s mean target price for INO is $10.25 while analysts mean recommendation is 1.60. Stock value has moved between $2.16 – 6.29 in last one year. Stock has got OUTPERFORM rating from 5 of Thomson Reuters analysts, 0 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for INO is $10.25 while analysts mean recommendation is 1.60.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) yearly performance is -26.16%. Annual EPS Growth of past 5 years is 6.10%. The current share price indicates that stock is -52.06% away from its one year high and is moving 40.47% ahead of its 52-week low.
On 26 June 2018, Odonate Therapeutics, Inc. (NASDAQ:ODT) shares gained 12.94% and ultimately finalized to $31.76 in last traded day. Stock has got OUTPERFORM rating from 2 of Thomson Reuters analysts, 0 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for ODT is $37.00 while analysts mean recommendation is 1.70.
At the movement Kadmon Holdings, Inc. (NYSE:KDMN) is under coverage by number of analysts. Buy rating has been given by 2 analysts to the company stock whereas 0 given UNDERPERFORM rating to stock and 0 given HOLD rating. The consensus recommendation by Thomson Reuters analysts is buy and their mean rating for the stock is 1.33 on scale of 1-5. Analysts mean target price for Kadmon Holdings, Inc. (NYSE:KDMN) is $12.97 while their mean recommendation is 1.50 (1=Buy, 5=sell).
If we look at stock performance in last active day trading, we see that stock has moved gained 11.52% to end the day at $1.84. The current share price indicate that stock is -58.09% away from its one year high and is moving 12.88% ahead of its 52-week low.
